Vorinostat Recruiting Phase 1 Trials for Renal Cell Adenocarcinoma / Urinary Bladder Neoplasms Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02619253Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma